Procalcitonin as an indicator of bacterial infection and co-infection in adult patients with Covid-19

Authors

  • Carlos Asdrubal Fienco Reyes Maestrante

Abstract

Infections are a frequent reason for consultation in health services and sometimes, due to their severity, they are related as bacterial, viral and fungal, which represents a health problem, even more so with the current Covid-19 pandemic. People infected by this virus tend to get complicated if it is not detected in time and in turn present untimely infections that symbolize an important economic cost and the well-being of the affected people. For this reason, procalcitonin has been classified as a proven infection marker for the early detection of complications of this pathology. The objective of this research work was to analyze procalcitonin as an indicator of infection and bacterial co-infection in adult patients with Covid-19. it was carried out under the documentary design modality, its approach was to collect updated information from different scientific and bibliographic sources, the applied methodology was descriptive with an explanatory level documentary design, the review of articles and documents of the last 5 years (2017-2022) investigated in Google Scholar, PubMed, Scielo, Medicina Intensiva, Medline, Elsevier, whose information was analyzed and presented for the contribution of knowledge of the procalcitonin analyte and its importance in contributing to health personnel as an early diagnosis of First line and targeted treatment for infectious diseases infectious diseases and the management of the Covid-19 pandemic, demonstrating an association of high concentrations of the analyte procalcitonin as a biomarker of disease severity.

Downloads

Download data is not yet available.

References

Ruiz Bravo A, Jimenez Valera M. SARS-CoV-2 y pandemia de síndrome respiratorio agudo (COVID-19). SCIELO. 2020 Junio; 61(2).

Uriol Mantilla CL, Vasquez Tirado GA. Ventilación espontánea en decúbito prono en pacientes con infección por SARS Cov-2 sin ventilación mecánica invasiva. Revista del Cuerpo Médico del HNAAA. 2020 Octubre; 13(4).

Lovelle O. Características epidemiológicas y clínicas de 99 casos de neumonía por el nuevo coronavirus de 2019 en Wuhan, China: un estudio descriptivo. Lancet. 2020 Febrero; 395(10223): p. 507-513.

Manrique Abril F, Mendez Fandiño Y, Herrera Amaya G, Rodriguez J, Manrique Abril R. Uso de procalcitonina como diagnóstico de sepsis o shock séptico: revisión sistemática y metaanálisis. Infectio: revista de la Asociacion Colombiana de Infectologia. 2019 Abril; 22(2).

Fienco Reyes C. Jipijapa; 2022.

Statista. [Online].; 2022 [cited 2022 Abril 8. Available from: https://es.statista.com/estadisticas/1107712/covid19-casos-confirmados-a-nivel-mundial-por-region/.

Covid19 Ecuador. [Online].; 2022 [cited 2022 Abril 8. Available from: https://www.covid19ecuador.org/.

De Francesco MA, Poiesi C, Gargiulo F, Bonfanti C, Pollara P, Fiorentini S, et al. Co-infection of chlamydia pneumoniae and mycoplasma pneumoniae with SARS-CoV-2 is associated with more severe features. The Journal of infection. 2021 Abril; 82(4).

Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2021 Enero; 27(1): p. 83-88.

Westblade LF, Simon MS, Satlin MJ. Bacterial coinfections in Coronavirus disease 2019. Trends in microbiology. 2021 Octubre; 29(10).

Elabbadi A, Turpin M, Gerotziafas GT, Teulier M, Voiriot G, Fartoukh M. Bacterial coinfection in critically ill COVID-19 patients with severe pneumonia. Infection. 2021 Enero; 49(3).

Sharov KS. SARS-CoV-2-related pneumonia cases in pneumonia picture in Russia in March-May 2020: Secondary bacterial pneumonia and viral co-infections. Journal of global health. 2020 Diciembre; 10(2).

Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. The Journal of infection. 2020 Agosto; 81(2).

Wang L, Amin AK, Khanna P, Aali A, McGregor A, Bassett P, et al. An observational cohort study of bacterial co-infection and implications for empirical antibiotic therapy in patients presenting with COVID-19 to hospitals in North West London. The journal of antimicrobial chemotherapy. 2020 Noviembre; 76(3).

Fattorini L, Creti R, Palma C, Pantosti A, Pathogens} ,. Bacterial coinfections in COVID-19: an underestimated adversary. Annali dell'Istituto superiore di sanita. 2020 Septiembre; 56(3): p. 359-364.

Zhu X, Ge Y, Wu T, Zhao K, Chen Y, Wu B, et al. Co-infection with respiratory pathogens among COVID-2019 cases. Virus research. 2020 Agosto; 285(1).

Nori P, Szymczak W, Puius Y, Sharma A, Cowman K, Gialanella P, et al. Emerging co-pathogens: New Delhi metallo-beta-lactamase producing Enterobacterales infections in New York city COVID-19 patients. International journal of antimicrobial agents. 2020 Diciembre; 56(6).

Kozak R, Prost K, Yip L, Williams V, Leis JA, Mubareka S. Severity of coronavirus respiratory tract infections in adults admitted to acute care in Toronto, Ontario. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology. 2020 Mayo; 126(10).

Sharifipour E, Shams S, Esmkhani M, Khodadadi J, Fotouhi Ardakani R, Koohpaei A, et al. Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU. BMC infectious diseases. 2020 Septiembre; 20.

Wolfisberg S, Gregoriano C, Schuetz P. Procalcitonin for individualizing antibiotic treatment: an update with a focus on COVID-19. Critical reviews in clinical laboratory sciences. 2022 Septiembre; 59 (1).

Menchén DA, Vázquez JB, Allende JMB, García GH. Neumonía vírica. Neumonía en la COVID-19. Medicine. 2022 Enero; 13(1).

Bibi A, Basharat N, Aamir M, Haroon ZH. Procalcitonin as a biomarker of bacterial infection in critically ill patients admitted with suspected Sepsis in Intensive Care Unit of a tertiary care hospital. Pakistan journal of medical sciences quarterly. 2021 Noviembre; 37(7).

Ramón NM, Miró AE, Martínez IS, Espín MA. Utilización de los niveles plasmáticos de procalcitonina en una unidad de cuidados intensivos. Revista cubana de farmacia. 2021 Noviembre; 50(2).

Bréchot N, Hékimian G, Chastre J, Luyt CE. Procalcitonin to guide antibiotic therapy in the ICU. International journal of antimicrobial agents. 2019 Didiembre; 46(1).

Schuetz P, Bolliger R, Merker M, Christ-Crain M, Stolz D, Tamm M, et al. Procalcitonin-guided antibiotic therapy algorithms for different types of acute respiratory infections based on previous trials. Expert review of anti-infective therapy. 2018 Julio; 16(7).

Hu R, Han C, Pei S, Yin M, Chen X. Procalcitonin levels in COVID-19 patients. International journal of antimicrobial agents. 2020 Junio; 56(2).

Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clinica chimica acta; international journal of clinical chemistry. 2020 Junio; 505(3): p. 190-191.

Published

2022-08-16

How to Cite

Fienco Reyes, C. A. (2022). Procalcitonin as an indicator of bacterial infection and co-infection in adult patients with Covid-19 . Revista Científica Arbitrada Multidisciplinaria PENTACIENCIAS - ISSN 2806-5794., 4(3), 331–341. Retrieved from https://editorialalema.org/index.php/pentaciencias/article/view/183

Issue

Section

Artículos originales